← Browse by Condition
Medical Condition

breast neoplasms

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for breast neoplasms sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

  • Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
  • Phase 1–4 studies from early safety trials to post-marketing surveillance
  • NIH, pharmaceutical sponsor, and academic medical center studies worldwide
  • AI-powered plain-language summary available for every trial listing

Frequently Asked Questions — breast neoplasms Clinical Trials

How many clinical trials are currently recruiting for breast neoplasms?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for breast neoplasms, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for breast neoplasms?
breast neoplasms research spans Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a breast neoplasms clinical trial?
Eligibility criteria for breast neoplasms trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
2
Top Sponsors
Xiangya Hospital of Central South University 1 trial
Meshalkin Research Institute of Pathology of Circulation 1 trial
Asan Medical Center 1 trial
Atossa Therapeutics, Inc. 1 trial
Valeria Chiu 1 trial

Recruiting Clinical Trials

NCT06938373
Recruiting

Development and Application of Accurate Detection Technology Based on Multimodal Data of Breast Cancer Comobid Depression

Enrollment
1,000 pts
Location
China
Sponsor
Xiangya Hospital of Central So...
View Trial →
NCT06069115
Recruiting

Radiotherapy Exposed Lung Injury: Effect on Functioning - Cohort

Enrollment
200 pts
Location
Russia
Sponsor
Meshalkin Research Institute o...
View Trial →
NCT06421285
Recruiting

Effect of Preoperative Exercise on the Prevention of Secondary Lymphedema in Breast Cancer Patients

Enrollment
60 pts
Location
South Korea
Sponsor
Asan Medical Center
View Trial →
NCT05607004 Phase 2
Recruiting

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Enrollment
87 pts
Location
United States
Sponsor
Atossa Therapeutics, Inc.
View Trial →
NCT07465393
Recruiting

Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors

Enrollment
66 pts
Location
Taiwan
Sponsor
Valeria Chiu
View Trial →
NCT01042379 Phase 2
Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Enrollment
5,000 pts
Location
United States
Sponsor
QuantumLeap Healthcare Collabo...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology